Dean A Fennell
Affiliation: Queen Mary
- Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesotheliomaDean A Fennell
Lung and Mesothelioma Unit, Department of Medical Oncology, St Bartholomew s Hospital, West Smithfield, London EC1A 7BE, United Kingdom
Lung Cancer 47:277-81. 2005..Quality of life assessed by Rotterdam symptom checklist was associated with stabilization or improvement of psychological well-being and lung symptoms in the majority of patients, but deterioration in physical symptoms...
- Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug developmentDean A Fennell
Department of Medical Oncology, Lung Cancer and Mesothelioma Research Group, St Bartholomew s Hospital, West Smithfield, London, UK
Lancet Oncol 5:354-62. 2004..This review discusses recent developments in apoptosis biology that are specific to mesothelioma and the therapeutic implications for this aggressive cancer...
- Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trialsDean A Fennell
Lung Cancer and Mesthelioma Unit, Department of Oncology, and the Institute of Cell and Molecular Science Pathology, St Bartholomew s Hospital, London, United Kingdom
J Clin Oncol 23:184-9. 2005..Our retrospective analysis set out to test the validity of the model as a prognostic tool in patients treated in three phase II trials at St Bartholomew's Hospital (London, United Kingdom) between 1999 and 2003...
- Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesotheliomaDean A Fennell
Lung and Mesothelioma Unit, Department of Medical Oncology, St Bartholomew s Hospital, West Smithfield, London, UK
Cancer 109:93-9. 2007..Malignant pleural mesothelioma (MPM) is a rapidly progressive lethal tumor. Treatment options remain limited and the outcome in recurrent disease is poor...
- Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancerDean A Fennell
Department of Medical Oncology, St Bartholomew s Hospital, London, United Kingdom
Int J Cancer 121:2575-7. 2007..3). QoL showed improvement in activity symptoms and stabilization of physical symptoms. As IPM was a well-tolerated regimen with activity in rSCLC, a phase III trial comparing this triplet with other regimens in this setting is warranted...
- Prognostic factors in mesotheliomaJeremy P C Steele
Mesothelioma Unit, Department of Medical Oncology, St Bartholomew s Hospital and Medical College, London EC1A 7BE, UK
Lung Cancer 49:S49-52. 2005..9 months [95% C.I.=8.5-11.3] for those in the worst group. The suggestion is that all clinical and biological factors relevant to prognosis should be recorded prospectively in mesothelioma patients selected for clinical trials...
- Pulmonary toxicity and cancer treatmentDean A Fennell
Lung Cancer and Mesothelioma Research Group, Department of Medical Oncology, St Bartholomew s Hospital, London
Hosp Med 65:462-5. 2004..This article discusses the mechanisms, common clinical features and risk factors for cytotoxic drug-induced pulmonary toxicity, and outlines general management principles...
- In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapyBryone J Kuss
Institute of Child Health, University College London, London, United Kingdom
Int J Cancer 98:128-33. 2002..It provides rationale for the investigation of therapy adjuvants such as antisense oligonucleotides in the treatment of this malignancy...
- Advances in the systemic therapy of malignant pleural mesotheliomaDean A Fennell
Centre for Cancer Research and Cell Biology, Queen s University Belfast, 97 Liburn Road, Belfast BT9 7BL, Northern Ireland, UK
Nat Clin Pract Oncol 5:136-47. 2008..Coupled with high-quality translational research, such developments have real potential to improve the outlook of patients at a time of increasing incidence...
- In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletionPeter W Szlosarek
Cancer Research UK Translational Oncology Laboratory, Barts and The London, UK
Clin Cancer Res 12:7126-31. 2006..In this study, we investigated the expression and biological significance of argininosuccinate synthetase (AS), a rate-limiting enzyme in arginine production...
- Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesotheliomaAndrea Sartore-Bianchi
Institute of Internal Medicine and Medical Oncology, IRCCS Policlinico San Matteo University Hospital, 1 27100 Pavia corrected Italy
Clin Cancer Res 13:5942-51. 2007..We aimed at verifying whether the proteasome inhibitor Bortezomib could abrogate NF-kappaB activity in MMe cells, leading to tumor cell death and may be established as a novel treatment for this aggressive neoplasm...
- Molecular and Immunological approachesDean A Fennell
Centre for Cancer Research and Cell Biology, Queen s University, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland
Lung Cancer 49:S87. 2005
- PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanismDeborah E Banker
Clinical Research Division, FHCRC, D1 100, 1124 Columbia Street, Seattle, WA 98104, USA
Leuk Res 26:91-106. 2002..Therefore, PK11195 might contribute to improved clinical outcomes in AML...
- Caspase regulation in non-small cell lung cancer and its potential for therapeutic exploitationDean A Fennell
Thoracic Oncology Research Group, Centre for Cancer Research and Cell Biology, Oncology, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland
Clin Cancer Res 11:2097-105. 2005..This review discusses current knowledge relating to caspase regulation in NSCLC and highlights novel strategies for reversing the apoptosis resistant phenotype, with potential to accelerate development of effective therapy...
- Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAILSandra Van Schaeybroeck
Drug Resistance Group, Center for Cancer Research and Cell Biology, Queen s University Belfast, Belfast, Northern Ireland
Cancer Res 68:8312-21. 2008....